Floatz logo

Bcma-Cd19 Ccar T Cells

Sjogren Syndrome

Peking University People's HospitalCell therapyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

10 Active assets in the Sjogren Syndrome cohort.

Asset / SponsorPhaseRating
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Peking Union Medical College Hospital
Phase 4BB
Belimumab
Peking Union Medical College Hospital
Phase 4B
Diluent
Instituto de Oftalmología Fundación Conde de Valenciana
Phase 3B
Car-Nk Cell
Bangdong Gong
Phase 1/2CCC
IMMUNOGLOBULIN G1, ANTI-(HUMAN LEUKOCYTE IG-LIKE RECEPTOR A4) (HUMAN MONOCLONAL VIB7734 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN MONOCLONAL VIB7734 .LAMBDA.-CHAIN, DIMER
Amgen
Phase 1CC

View all 11 →

Same molecule, other indications

Bcma-Cd19 Ccar T Cells is also rated in:

myositis diseaseDormant
CCC
Indicative ·
53 / 100
View asset →
systemic lupus erythematosusDormant
CCC
Indicative ·
53 / 100
View asset →
systemic sclerosisDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →